Update in medical therapy of ulcerative colitis: a practical approach.
The bewildering array of medications in the therapy of inflammatory bowel disease (IBD) often confounds the clinician in the choice of specific agents regarding the balance between safety and efficacy. This review surveys and evaluates currently available IBD therapies as well as those used in clinical trials of ulcerative colitis. The primary purpose is to provide the busy clinician with a practical guide to the use of established and newly emerging medical therapies of IBD.
Katz
Seymour
S
New York University School of Medicine, North Shore University Hospital-Long Island Jewish Health Systems, and St. Francis Hospital, Great Neck, New York, USA. SKAK366@aol.com
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000636:Aminosalicylic Acids / Q000191:economics / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic; D011306:Prescription Fees; D012074:Remission Induction; D012720:Severity of Illness Index
D000276:Adjuvants, Immunologic; D000636:Aminosalicylic Acids; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids